Emerson, Scott S.

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 3,236

The prevention and treatment of missing data in clinical trials

Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine

Statistical Methods and Bayesian InferenceStatistical Methods in Clinical Trials

Cited by 1,884

The Importance of the Normality Assumption in Large Public Health Data Sets

Lumley, T., Diehr, P., Emerson, S., & Chen, L. (2002) · Annual Review of Public Health

Statistical Methods in EpidemiologyProbability and Statistical Research

Cited by 1,803

Efficacy and safety of degludec versus glargine in type 2 diabetes.

Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 574

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

McGuire, D. K., Marx, N., Mulvagh, S. L., Deanfield, J. E., Inzucchi, S. E., Pop-Busui, R., Mann, J. F. E., Emerson, S. S., Poulter, N. R., Engelmann, M. D. M., et al. (2025) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 416

Chromosomal instability in ulcerative colitis is related to telomere shortening

O'Sullivan, J. N., Bronner, M. P., Brentnall, T. A., Finley, J. C., Shen, W.-T., Emerson, S., Emond, M. J., Gollahon, K. A., Moskovitz, A. H., Crispin, D. A., et al. (2002) · Nature Genetics

Telomeres, Telomerase, and SenescenceInflammatory Bowel Disease

Cited by 346

Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design

Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., Kushner, R. F., Marso, S., Plutzky, J., Brown-Frandsen, K., et al. (2020) · American Heart Journal

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 249

Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility

Alexander, G. C., Emerson, S., & Kesselheim, A. S. (2021) · JAMA

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 240

Revisiting FDA Approval of Aducanumab

Alexander, G. C., Knopman, D. S., Emerson, S. S., Ovbiagele, B., Kryscio, R. J., Perlmutter, J. S., & Kesselheim, A. S. (2021) · New England Journal of Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 162

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

Deanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., et al. (2025) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 143

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

Lingvay, I., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt‐Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · Obesity

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 113

Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial

Marx, N., Deanfield, J. E., Mann, J. F. E., Arechavaleta, R., Bain, S. C., Bajaj, H. S., Bayer Tanggaard, K., Birkenfeld, A. L., Buse, J. B., Davicevic-Elez, Z., et al. (2025) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 70

Bio-creep in non-inferiority clinical trials

Everson‐Stewart, S., & Emerson, S. S. (2010) · Statistics in Medicine

Statistical Methods in Clinical TrialsMeta-analysis and systematic reviews

Cited by 64

Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials

Lee, M. M. Y., Sattar, N., Pop-Busui, R., Deanfield, J., Emerson, S. S., Inzucchi, S. E., Mann, J. F. E., Marx, N., Mulvagh, S. L., Poulter, N. R., et al. (2025) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 63

Approval policies for modifications to machine learning‐based software as a medical device: A study of bio‐creep

Feng, J., Emerson, S., & Simon, N. (2021) · Biometrics

Statistical Methods in Clinical TrialsHealthcare Regulation

Cited by 26

The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes

Lübker, C., Bhavsar, J., Duque do Vale, R., Emerson, S. S., Nørtoft, E., Plutzky, J., Roberts, G., Tarp, J. M., & Lincoff, A. M. (2025) · Advances in Therapy

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 5

Semaglutide, inflammatory markers and cardiovascular outcomes in patients with overweight or obesity in the SELECT trial

Plutzky, J., Bogdański, P., Dagdelen, S., Deanfield, J., Emerson, S., Hovingh, G., Kahn, S., Larsen, S., Latkovskis, G., Lehrke, M., et al. (2024) · Atherosclerosis

Adipokines, Inflammation, and Metabolic DiseasesDiabetes Treatment and Management

Cited by 2